TNGX
$18.68
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
Intraday
Recent News
Tango Therapeutics’ (TNGX) Sees Cautious Analyst Optimism Following Earnings
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 11 Best Day Trading Stocks to Buy Now. Financial firm Mizuho raised its share price target for Tango Therapeutics Inc. (NASDAQ:TNGX) on March 11th. It slightly adjusted the target to $20 from $19 and kept an Outperform rating on the stock. Mizuho’s coverage came after the precision […]
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 6, Wedbush increased the firm’s price target on Tango Therapeutics Inc. (NASDAQ:TNGX) from $15 to $19 following the company’s fourth quarter financial results and corporate updates. The firm maintained an Outperform rating on the […]
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts. All three names carry verified Buy or Overweight ratings, and the gap between current trading prices and analyst targets ranges from substantial to dramatic. Three Calls, Three Catalysts ... X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango’s Dual-Target Trial Collaboration?
In early March 2026, Tango Therapeutics and Erasca announced a clinical trial collaboration and supply agreement to test Erasca’s pan-RAS molecular glue ERAS-0015 with Tango’s PRMT5 inhibitor vopimetostat in MTAP-deleted pancreatic and RAS-mutant non-small cell lung cancer. The combination seeks to exploit the dependency created by co-occurring MTAP deletions and RAS mutations, aiming for a dual-targeted approach that could more effectively shut down RAS signaling and PRMT5 activity in...
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.